| Date Filed | Type | Description |
| 10/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/21/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 6.9% stake in Benitec Biopharma Inc. |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/11/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 4% stake in Expensify, Inc. |
| 07/27/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.9% stake in Semper Paratus Acquisition Corporation |
| 07/10/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.1% stake in Janux Therapeutics, Inc. |
| 07/03/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.1% stake in Nektar Therapeutics |
| 07/03/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.7% stake in Clene Inc. |
| 06/12/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.9% stake in Lyra Therapeutics, Inc. |
| 06/09/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 6% stake in Inflection Point Acquisition Corp. II |
| 05/19/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 6.1% stake in ACELYRIN, Inc. |
| 05/19/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 4.9% stake in PMV Pharmaceuticals, Inc. |
| 05/19/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.5% stake in Alchemy Investments Acquisition Corp 1 |
| 05/19/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 6.2% stake in Coherus Biosciences, Inc. |
| 05/15/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 6.7% stake in Magenta Therapeutics, Inc. |
| 05/01/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.2% stake in 2seventy bio, Inc. |
| 04/03/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.1% stake in Design Therapeutics, Inc. |
| 03/14/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.4% stake in Western Alliance Bancorporation |
| 03/06/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.6% stake in Enliven Therapeutics, Inc. |
| 02/27/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.2% stake in Annexon, Inc. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 4.9% stake in AltC Acquisition Corp. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 3.6% stake in Gores Holdings IX, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| CITADEL ADVISORS LLC reports a |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 7.4% stake in MoonLake Immunotherapeutics |
|